<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115659</url>
  </required_header>
  <id_info>
    <org_study_id>CZKIPLA-ADPKD-002</org_study_id>
    <nct_id>NCT02115659</nct_id>
  </id_info>
  <brief_title>Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)</brief_title>
  <official_title>Randomized Controlled Trial of Triptolide-Containing Formulation for Autosomal Dominant Polycystic Kidney Disease (ADPKD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triptolide was shown in experimental studies to inhibit the cyst formation and growth in
      ADPKD models, while triptolide-containing formulation was revealed to potentially slow the
      disease progression in several proteinuric ADPKD patients in our clinical practice. It
      remains to be shown the effect of triptolide-containing formulation on total kidney volume
      (TKV) enlargement and renal function protection in ADPKD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized Controlled Trial
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal volume measured by high resolution magnetic resolution imaging</measure>
    <time_frame>2 yrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>2 yrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events.</measure>
    <time_frame>2 yrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease (ADPKD)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus standard treatment. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triptolide-Containing Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triptolide-Containing Formulation (1mg/kg/d) was prescribed; Dosage will be adjusted if necessary according to the adverse events monitoring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptolide-Containing Formulation</intervention_name>
    <description>Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.</description>
    <arm_group_label>Triptolide-Containing Formulation</arm_group_label>
    <other_name>Triptolide-Containing Formulation plus standard treatment.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo plus standard treatment.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ADPKD patient older then 40 years of age without gender limitation

          -  Estimated glomerular filtration rate (eGFR) higher than 60 ml/min 1.73m2

          -  documented kidney volume progression with yearly increasing rate more than 6%

          -  informed consent

        Exclusion Criteria:

          -  Female who is planning to become pregnant, who is pregnant and/or lactating, who is
             unwilling to use effective means of contraception

          -  impaired liver function as increased liver enzymes (2-fold above normal values)

          -  uncontrolled hypercholesterolemia (fasting cholesterol &gt; 8 mmol/l) or
             hypertriglyceridaemia (&gt; 5 mmol/l) under lipid lowering therapy

          -  granulocytopenia (white blood cell &lt; 3,000/mm3) or thrombocytopenia (platelets &lt;
             100,000/mm3)

          -  hepatitis B or C, HIV infection

          -  malignancy

          -  mental illness that interfere with the patient ability to comply with the protocol

          -  drug or alcohol abuse

          -  known hypersensitivity to similar drugs as Triptolide-Containing Formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changlin Mei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Changzheng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changlin Mei, MD</last_name>
    <email>chlmei1954@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changlin Mei, MD</last_name>
      <email>chlmei1954@126.com</email>
    </contact>
    <investigator>
      <last_name>Changlin Mei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <last_update_submitted>April 16, 2014</last_update_submitted>
  <last_update_submitted_qc>April 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Mei changlin</investigator_full_name>
    <investigator_title>Professor,Director of the Kidney Institute</investigator_title>
  </responsible_party>
  <keyword>ADPKD</keyword>
  <keyword>triptolide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Triptolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

